Home / Stocks / Anuh Pharma Limited
ANUHPHR

Anuh Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹79.76

Change

+0.16 (0.2%)

Open

₹79.6

Prev. Close

₹79.6

Day High

₹80.85

Day Low

₹79.0

Volume Analysis

Traded

65,092

Delivered

38,116

Delivery %

58.56%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (0)

No signal for this stock

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹82.59 ₹81.72 ₹80.74 ₹79.87 ₹78.89 ₹78.02 ₹77.04
Fibonacci ₹81.72 ₹81.01 ₹80.58 ₹79.87 ₹79.16 ₹78.73 ₹78.02
Camarilla ₹80.27 ₹80.1 ₹79.93 ₹79.87 ₹79.59 ₹79.42 ₹79.25

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+1.36%

1 Week

-3.76%

1 Month

-0.14%

3 Months

+4.91%

6 Months

+5.53%

1 Year

-0.61%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

11.37%

Net margin 5.31% × asset turnover 1.39x × equity multiplier 1.54x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Anuh Pharma Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 56/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising.

TopFund Score — Fundamentals Quality

56/100 — Average

Data confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

47

Cash Flow

0

Corporate Governance

100

Institutional Ownership

30

Business Quality

53

Risk & Volatility

62

Liquidity

38

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Anuh Pharma inaugurated Tarapur plant on 15 Nov 2026; capacity rises by 525 MT to 2,925 MT annually.

Anuh Pharma inaugurated F-10/1 Tarapur plant; 525 MT/year capacity to be added by December 2026.

Investor Presentation for Q2 and H1 FY 2026-27

Newspaper Publication of the Unaudited Financial Results for the Quarter and half year ended 30th September, 2026, published in the Financial Express in English Language …

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 150 172 164 138 166 160 198 186 186 197 202 194 185
Expenses + 132 148 145 127 149 145 179 176 174 178 182 178 168
Operating Profit 18 24 19 11 17 15 19 10 12 19 20 16 17
OPM % 12.0% 14.0% 12.0% 8.0% 10.0% 9.0% 9.0% 6.0% 6.0% 10.0% 10.0% 8.0% 9.0%
Other Income + 2 4 3 4 3 1 1 3 1 2 -1 3 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 2 2 2 2 2 2 3 3 3 3 3 2 2
Profit before tax 18 25 20 12 18 13 17 11 10 18 16 17 15
Tax % 23.0% 24.0% 22.0% 22.0% 17.0% 22.0% 28.0% 24.0% 23.0% 25.0% 25.0% 32.0% 25.0%
Net Profit + 14 19 15 10 15 10 12 8 8 13 12 11 11
EPS in Rs 1 2 2 1 2 1 1 1 1 1 1 1 1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 30 24 4 -15 11 -7 21 35 12 24 2 4 0

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 284 326 206 238 321 307 432 487 527 647 662 772
Expenses + 253 289 183 220 291 284 387 439 476 571 600 709
Operating Profit 31 38 23 18 30 23 45 47 52 76 62 62
OPM % 11.0% 12.0% 11.0% 8.0% 9.0% 8.0% 10.0% 10.0% 10.0% 12.0% 9.0% 8.0%
Other Income + 5 4 8 7 5 4 11 5 6 12 9 4
Interest 1 1 1 0 1 1 2 2 1 1 1 1
Depreciation 3 2 2 2 2 7 15 12 10 9 9 11
Profit before tax 32 38 28 23 32 19 39 39 47 78 61 54
Tax % 31.0% 32.0% 27.0% 29.0% 28.0% 25.0% 26.0% 22.0% 24.0% 23.0% 22.0% 24.0%
Net Profit + 22 26 20 17 23 14 28 31 36 60 47 41
EPS in Rs 2 3 2 2 2 1 3 3 4 6 5 4
Dividend Payout % 27.0% 24.0% 31.0% 42.0% 29.0% 48.0% 26.0% 29.0% 28.0% 21.0% 16.0% 37.0%
Sales growth 7 15 -37 16 35 -4 41 13 8 23 2 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 97 107 128 137 152 150 166 189 216 266 301 302 310
Borrowings + 0 2 0 2 4 45 14 4 1 3 11 0 19
Other Liabilities + 67 71 48 57 71 119 128 129 163 152 170 205 174
Total Liabilities 168 193 189 209 240 326 333 347 405 446 507 557 554
Fixed Assets + 9 18 17 17 21 84 71 61 53 49 58 57 53
CWIP 0 0 0 6 34 0 0 0 0 0 0 0 0
Investments 43 43 70 66 39 80 31 43 91 97 106 84 113
Other Assets + 116 131 101 120 147 163 230 243 261 300 342 416 387
Total Assets 168 193 189 209 240 326 333 347 405 446 507 557 554
Equity Capital 4 13 13 13 13 13 25 25 25 25 25 50 50

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + 19 16 26 2 7 49 -19 29 54 13 37 -3
Cash from Investing Activity + -12 -5 -20 2 3 -77 52 -8 -43 1 -20 18
Cash from Financing Activity + -8 -9 -4 -5 -7 22 -33 -19 -12 -9 -5 -26
Net Cash Flow -1 2 2 -1 3 -5 0 2 -2 5 12 -12
Free Cash Flow 18 6 25 -5 -22 13 -25 27 52 8 17 -11
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 96 78 149 49 56 232 -20 80 130 42 78 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 69.94% → 71.79%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 30.05% 29.96% 30.05% 30.06% 30.07% 30.04% 30.04% 28.19% 28.17% 28.14% 28.19% 28.07%
Promoters 69.94% 69.91% 69.91% 69.91% 69.91% 69.91% 69.91% 71.81% 71.81% 71.79% 71.79% 71.79%
FII 0.0% 0.03% 0.03% 0.02% 0.02% 0.04% 0.04% 0.0% 0.0% 0.05% 0.01% 0.11%
DII 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Anuh Pharma Limited (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Anuh Pharma Limited?

Frequently Asked Questions about Anuh Pharma Limited

Community Sentiment

What are other investors saying about Anuh Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.